Shenzhen, September 2, 2022 / PRNewswire/ -- August 24, Libang Instruments (300206. SZ) released its 2022 semi-annual report. In the first half of 2022, the operating income was 858 million yuan. Among them, the net profit in the second quarter exceeded 100 million yuan, an increase of 66.78% year-on-year and a quarter-on-quarter increase of 103.56%. Coupled with the company's competitive advantages accumulated in research and development, production, sales and other aspects over the years, the future growth momentum is sufficient, and the annual performance target can be expected.
Steady and rising, strengthen the core market advantages
During the reporting period, the performance of Libang's various business segments maintained steady development, with gross profit margins between 47% and 65%, and product competitiveness and profitability remained strong. In the ultrasound imaging sector, after years of continuous layout, ultrasonic products cover the needs of high-, medium, and low-level users, and the advantages of products, channels, hospitals, etc. accumulated in the early stage are gradually realized, and the ultrasonic imaging sector in the first half of 2022 achieved revenue of 116 million yuan, an increase of 29.91% year-on-year. In the maternal and child health sector, the company takes the fetal monitoring products as the starting point, continuously improves the application of products in the field of maternal and child health, and provides women's life cycle health management programs such as cervical health screening, maternal and fetal monitoring to pelvic floor rehabilitation diagnosis and treatment. In the first half of 2022, the maternal and child health sector achieved revenue of 151 million yuan, an increase of 9.38% year-on-year.
In the first half of the year, Libang made a stunning appearance overseas with new products for inspection and monitoring, and the new generation of i20 blood gas, blood oxygen and electrolyte analyzer provided a comprehensive solution for blood gas analysis for clinical practice; The new generation of iX Series monitors is a unique and innovative technology in the industry to create the ultimate clinical comfort experience. The two new products are expected to be officially released in the domestic market in the second half of the year.
Libang's maternal and child health, ECG diagnosis, blood gas, patient monitoring series are in the head position of domestic manufacturers, and have strong competitiveness in the field of ultrasound and in vitro diagnosis. In the future, we will continue to consolidate the market advantage position of our core business and further enhance our brand influence, channel coverage and market share.
R&D is accumulated, and innovation expands new growth points
Libang continued to strengthen R & D investment, R & D expenses in the first half of 2022 was 131 million yuan, long-term high R & D investment in the company in maternal and child pelvic floor rehabilitation business, molecular diagnosis business, smart medical and other emerging businesses continue to innovate and expand.
Libang uses its own brand and resource advantages of obstetrics and gynecology to see the opportunity to cut into the pelvic floor field and drive the growth of pelvic floor equipment, thereby breaking through the upper limit space of a single product. In 2022, we will build an overall solution for intelligent magnetoelectric combined pelvic floor rehabilitation, and launch a new generation of portable pelvic floor pressure screening equipment PA4 screening version. The nucleic acid detection products of the new coronavirus, influenza A virus, influenza B virus and respiratory syncytial virus launched by the molecular diagnostic business platform have obtained THE EU CE certification in May and are expected to be released in overseas markets in the fourth quarter of 2022.
In the field of smart medical care, Relying on the core technology and channel advantages of the five major hardware product lines, combined with advanced medical information technology and the concept of "Internet +", Libang has further enriched the solutions in the smart medical market, and gradually transformed from a medical device product supplier to an information-based comprehensive solution provider that enhances the overall diagnosis and treatment capabilities of medical institutions. For example, the wisdom heart network through real-time transmission of ECG data, centralized diagnosis, and data sharing between upper and lower medical institutions has realized "the patient has not arrived, the information arrives first", so that there is no missing diagnosis and no delay, and the treatment of patients is raced against the clock. In the field of women and children, the formation of regional maternal health management from the hospital to the community, remote fetal supervision is to extend the scope of medical services to the family, so as to achieve early detection, timely diagnosis and treatment, reduce the high-risk incidence rate caused by disease delay outside the hospital. Up to now, Libang has completed the information network construction of more than 5,000 medical institutions and clinical departments in the hospital, including Wuhan Asian Heart Hospital, Hunan Provincial People's Hospital, Shenzhen People's Hospital and other large-scale tertiary hospitals.
Relying on the advantages of global platform, technology and channels, Libang's focus on cultivating and R&D innovation in emerging businesses will provide new growth points for the rapid development of future business. At the same time, with the acceleration of medical informatization construction in mainland China, Libang will continue to take "Libang Cloud" as the business core of smart medical care, accelerate the frontier of medical informatization and the clinical application of artificial intelligence by integrating new technologies and concepts such as cloud computing, Internet of Things, artificial intelligence, and 5G, continuously improve the moat of terminal market competition, and help the main business to continue to grow steadily.
The global channel is leading the way and developing new opportunities
As an international medical device company, Libang has always adhered to the development strategy of globalization. After more than 20 years of in-depth accumulation of promoting the global layout, Libang has set up 4 major R&D centers and 18 subsidiaries around the world, and the service team in the United Kingdom, the United States, Germany, India and other countries has begun to take shape, with a strong international-led channel and terminal coverage capabilities, and the core advantages of integrating global medical resources are obvious.
Since 2022, Lebon has accelerated its expansion into overseas markets, successfully entering a large number of overseas high-end users such as Queen Mary Hospital (Hong Kong), Derriford Hospital (UK), University Medical Centre Maribor Slovenia (Slovenia) and Mae Fah Luang University Hospital (Thailand). As the globalization strategy continues to deepen, the international influence of the EDAN brand has been rapidly enhanced, laying a solid foundation for more product penetration in the future.
In addition, with the introduction of public hospitals in the first half of the year to purchase domestic equipment policy, domestic medical equipment will surely usher in the peak of configuration, and then domestic excellent medical brands will also usher in the rapid development of "time, place and people". Through the integration of technological innovation capabilities, supply chain capabilities, global channel capabilities, multi-production line collaboration capabilities, and information service capabilities, Libang will usher in new growth opportunities for domestic substitution.
In the first half of the year, in the face of the complex environment of repeated epidemics, Libang relied on R&D and innovation capabilities, global channel advantages, and product quality advantages to maintain steady development; With its outstanding brand influence, it has won a number of authoritative awards in the industry: Excellent National Brand Award, Most Social Responsibility Award, Guardianship and Emergency Examination Product Line Gold Award. Looking forward to the second half of the year, we will adhere to the core concept of "customer-centric", consolidate the three core organizational capabilities of customer orientation, efficient collaboration and the pursuit of excellence, and lead the realization of the overall strategic goals.
This article originated from PR Newswire